In June 2022, President Biden announced the Americas Partnership for Economic Prosperity (APEP) with eleven other countries in the Western Hemisphere. The White House declared APEP a “historic new agreement to drive our hemisphere’s economy recovery and growth,” including through strengthening supply chains, incentivizing private-sector investment and addressing regulatory issues to make regional trade more resilient.
More than two years later, on June 20, 2024, the Office of the United States Trade Representative (USTR) finally requested input from the U.S. business community and other public stakeholders concerning U.S. interests and priorities regarding APEP.
As PhRMA notes in its recent comment letter, USTR’s intentionally unambitious and vague APEP strategy has failed to deliver meaningful results for American workers and businesses. USTR’s list of priorities for APEP indefensibly excludes longstanding and bipartisan U.S. trade objectives — such as protecting intellectual property and actively dismantling foreign trade barriers — that protect American workers from unfair competition abroad.
As PhRMA’s comments explain, these and other trade objectives, such as eliminating regulatory barriers that impede U.S. biopharmaceutical exports, are essential to:
- Expand export and economic opportunities for American workers and companies
- Incentivize the invention and production of lifesaving medicines, and
- Reinforce the resilience of U.S. biopharmaceutical supply chains in the Western Hemisphere.
Unfortunately, USTR’s lack of serious purpose concerning APEP is merely the latest example of the Administration’s misguided and often harmful approach to trade policy, which holds negative consequences for American workers and U.S. businesses facing stiff global competition.
Douglas Petersen
Douglas Petersen is PhRMA’s Vice President for international trade. Previously, he was international trade counsel for the U.S. Senate Committee on Finance, an international trade attorney with White & Case LLP and a trade policy analyst at the Cato Institute. He received a law degree from New York University, a graduate degree from the London School of Economics, and undergraduate degrees from the University of Utah.
Douglas Petersen
PhRMA highlights need for Germany to pay its fair share
New “America Cures” ad: U.S. patients get new medicines first
New analysis highlights access to new medicines in the United States and abroad
USTR’s 2026 Special 301 Report stands up for American innovation
No Region Left Behind: USTR expands its unambitious trade agenda to the western hemisphere
International
Trade
No Region Left Behind: USTR expands its unambitious trade agenda to the western hemisphere
No Region Left Behind: USTR expands its unambitious trade agenda to the western hemisphere